Jeffrey S. Aronin

As Chairman and CEO of Paragon Biosciences, Jeffrey Aronin has launched several successful portfolio companies, including: Harmony Biosciences, Castle Creek Pharma, Emalex Biosciences, and Skyline Biosciences. These portfolio companies are developing innovative therapies for severe diseases. Focus areas include: biopharmaceuticals, AI-enabled life science products, and advanced treatments such as cell and gene therapies.

Previously, Mr. Aronin founded Ovation Pharmaceuticals, where he served as President and CEO from 2000 to 2009, leading an organization that developed medicines which earned four novel drug approvals from the FDA . After Ovation was acquired by Lundbeck A/S in 2009, Mr. Aronin served as CEO of Lundbeck Inc. until 2011.

Jeffrey Aronin also founded Marathon Pharmaceuticals, where he served as Chairman and CEO from 2011 to 2017. Marathon developed medicines for rare diseases, successfully sold five medicines, and earned FDA approval for another, which was subsequently acquired by PTC Therapeutics.